Regulatory Guidance Monthly Review - February 2024
Stay up-to-date with the latest regulatory guidance updates from the FDA in February 2024. From clinical trial regulations to drug approvals, this...
Extending our scientific depth across allergy, dermatology, ophthalmology, respiratory, women's health, and more.
Each month, Veristat's regulatory team tracks and shares a selection of new Regulatory Guidance updates from the US Food & Drug Administration (FDA) that are pertinent to the governance of clinical trials and drug, biologic, or medical device development and approval.

Drugs for the Treatment of Partial Onset Seizures: Extrapolation of Efficacy from Adults to Pediatric Patients 1 Month of Age and Older (published 15-Jul-2024)
Download FDA Guidance
Blood Pressure and Pulse Donor Eligibility Requirements – Compliance Policy (published 17-Jul-2024)
Download FDA Guidance
Clinical Pharmacology Considerations for Human Radiolabeled Mass Balance Studies (published 18-Jul-2024)
Download FDA Guidance
Recommendations for Investigational and Licensed COVID-19 Convalescent Plasma (published 21-Jul-2024)
Download FDA Guidance
Container Closure System and Component Changes: Glass Vials and Stoppers (published 24-Jul-2024)
Download FDA Guidance
Real-World Data: Assessing Electronic Health Records and Medical Claims Data To Support Regulatory Decision-Making for Drug and Biological Products (published 25-Jul-2024)
Download FDA Guidance
M14 General Principles on Plan, Design, and Analysis of Pharmacoepidemiological Studies That Utilize Real-World Data for Safety Assessment of Medicines (published 05-Jul-2024)
Draft FDA Guidance
Purpose and Content of Use-Related Risk Analyses for Drugs, Biological Products, and Combination Products (published 08-Jul-2024)
Draft FDA Guidance
Pediatric Inflammatory Bowel Disease: Developing Drugs for Treatment (published 22-Jun-2024)
Draft FDA Guidance
Postapproval Manufacturing Changes to Biosimilar and Interchangeable Biosimilar Products Questions and Answers (published 23-Jul-2024)
Draft FDA Guidance
Approval Date: 07/02/2024
Drug Name: KISUNLABLA #761248
Active Ingredients: DONANEMAB-AZBT
Submission Classification*:
Review Priority**:
Company: ELI LILLY CO
Approval Date: 07/11/2024
Drug Name: VASOPRESSIN IN SODIUM CHLORIDE 0.9%NDA #217766
Active Ingredients: VASOPRESSIN
Submission Classification*: Type 3 - New Dosage Form
Review Priority**: Standard
Company: LONG GROVE PHARMS
Approval Date: 07/13/2024
Drug Name: MEDICAL AIR, USPNDA #219709
Active Ingredients: MEDICAL AIR
Submission Classification*:
Review Priority**: Unknown
Company: WSM SUPPLIER LLC
Approval Date: 07/17/2024
Drug Name: VOQUEZNANDA #218710
Active Ingredients: VONOPRAZAN FUMARATE
Submission Classification*: Type 9 - New Indication Submitted as Distinct NDA, Consolidated with Original NDA after Approval
Review Priority**: Standard
Company: PHATHOM PHARMACEUTICALS INC
Approval Date: 07/18/2024
Drug Name: ZITUVIMET XRNDA #216778
Active Ingredients: METFORMIN HYDROCHLORIDE; SITAGLIPTIN
Submission Classification*: Type 5 - New Formulation or New Manufacturer
Review Priority**: Standard
Company: ZYDUS
Approval Date: 07/19/2024
Drug Name: EPYSQLIBLA #761340
Active Ingredients: ECULIZUMAB-AAGH
Submission Classification*:
Review Priority**:
Company: SAMSUNG BIOEPIS CO LTD
Approval Date: 07/22/2024
Drug Name: OPIPZANDA #216655
Active Ingredients: ARIPIPRAZOLE
Submission Classification*: Type 3 - New Dosage Form
Review Priority**: Standard
Company: XIAMEN LP PHARM CO
Approval Date: 07/22/2024
Drug Name: FEMLYVNDA #218718
Active Ingredients: ETHINYL ESTRADIOL; NORETHINDRONE ACETATE
Submission Classification*: Type 3 - New Dosage Form
Review Priority**: Standard
Company: MILLICENT PR
Approval Date: 07/25/2024
Drug Name: LEQSELVINDA #217900
Active Ingredients: DEURUXOLITINIB PHOSPHATE
Submission Classification*: Type 1 - New Molecular Entity
Review Priority**: Standard
Company: SUN PHARM INDS INC
Approval Date: 07/25/2024
Drug Name: APREPITANTNDA #218754
Active Ingredients: APREPITANT
Submission Classification*: Type 5 - New Formulation or New Manufacturer
Review Priority**: Standard
Company: AZURITY
Approval Date: 07/26/2024
Drug Name: ERZOFRINDA #216352
Active Ingredients: PALIPERIDONE PALMITATE
Submission Classification*: Type 5 - New Formulation or New Manufacturer
Review Priority**: Standard
Company: LUYE INNOMIND PHARMA
Approval Date: 07/26/2024
Drug Name: POTASSIUM PHOSPHATES IN 0.9% SODIUM CHLORIDENDA #218343
Active Ingredients: POTASSIUM PHOSPHATE, DIBASIC; POTASSIUM PHOSPHATE, MONOBASIC
Submission Classification*: Type 5 - New Formulation or New Manufacturer
Review Priority**: Standard
Company: AMNEAL
Approval Date: 07/26/2024
Drug Name: ZUNVEYLNDA #218549
Active Ingredients: BENZGALANTAMINE GLUCONATE
Submission Classification*: Type 2 - New Active Ingredient and Type 3 - New Dosage Form
Review Priority**: Standard
Company: ALPHA COGNITION
Approval Date: 07/29/2024
Drug Name: TEZRULYNDA #218139
Active Ingredients: TERAZOSIN HYDROCHLORIDE
Submission Classification*: Type 3 - New Dosage Form
Review Priority**: Standard
Company: NOVITIUM PHARMA
09/09/2024 Antimicrobial Drugs Advisory Committee Meeting- 09:00 AM EDT to 04:15 PM EDT
09/13/2024 Gastrointestinal Drugs Advisory Committee Meeting- 08:30 AM EDT to 05:00 PM EDT
09/18/2024 Pediatric Advisory Committee Meeting- 10:00 AM EDT to 04:00 PM EDT
09/20/2024 Vaccines and Related Biological Products Advisory Committee Meeting- 08:30 AM EDT to 05:00 PM EDT

IMDRF publishes AI/ML guiding principles echoing US, UK, Canadian regulators (published 01-Jul-2024)
Read Article on RAPS.org
FDA again warns Sun Pharma over Dadra facility (published 02-Jul-2024)
Read Article on RAPS.org
EMA proposes revamping COVID-19 vaccine guidance for the post-pandemic era (published 03-Jul-2024)
Read Article on RAPS.org
FDA draft guidance aims to give companies leeway to address medical misinformation (published 08-Jul-2024)
Read Article on RAPS.org
FDA releases draft guidance on use-related risk analysis for combo products (published 09-Jul-2024)
Read Article on RAPS.org
Industry, research push for clarity in clinical trial eligibility guidances (published 09-Jul-2024)
Read Article on RAPS.org
Lab industry seeks more flexibility in FDA emergency enforcement guidance (published 10-Jul-2024)
Read Article on RAPS.org
European Commission drug shortage pilot study highlights industry, regulatory challenges (published 11-Jul-2024)
Read Article on RAPS.org
FDA issues final guidance user fees for combination products (published 16-Jul-2024)
Read Article on RAPS.org
FDA guidance addresses developing treatments for pediatric IBD (published 17-Jul-2024)
Read Article on RAPS.org
FDA unveils rare disease innovation hub, plans public meeting this fall (published 18-Jul-2024)
Read Article on RAPS.org
FDA makes exception for antibody drug conjugates in mass balance studies final guidance (published 18-Jul-2024)
Read Article on RAPS.org
FDA scolds’ Chinese firm for data integrity lapses, MIT for BIMO violations (published 19-Jul-2024)
Read Article on RAPS.org
European Commission president proposes new legislation to boost pharma competitiveness (published 22-Jul-2024)
Read Article on RAPS.org
Biosimilars: FDA draft guidance addresses manufacturing changes (published 22-Jul-2024)
Read Article on RAPS.org
EMA addendum addresses vaccine development for immunocompromised people (published 23-Jul-2024)
Read Article on RAPS.org
Oligonucleotides: EMA drafts new guideline on manufacturing and development (published 23-Jul-2024)
Read Article on RAPS.org
FDA finds data integrity, sterility problems at Indian drugmaker (published 25-Jul-2024)
Read Article on RAPS.org
FDA finalizes guidance on RWD from electronic health records (published 25-Jul-2024)
Read Article on RAPS.org
FDA finalizes COVID-era guidance on container closure changes (published 26-Jun-2024)
Read Article on RAPS.org
Swissmedic survey finds drug approval timelines slower than EMA, FDA (published 29-Jul-2024)
Read Article on RAPS.org
FDA dings Kaleo over Instagram post with insufficient risk information (published 29-Jul-2024)
Read Article on RAPS.org
EMA, Gates Foundation back pilot for African continental drug evaluations (published 30-Jul-2024)
Read Article on RAPS.org

Stay up-to-date with the latest regulatory guidance updates from the FDA in February 2024. From clinical trial regulations to drug approvals, this...
Stay up-to-date with the latest regulatory guidance updates from the FDA in December 2023. From clinical trial regulations to drug approvals, this...
Stay up-to-date with the latest regulatory guidance updates from the FDA in October 2023. From clinical trial regulations to drug approvals, this...